-ThromboGenics NV  has announced that the FDA has accepted the filing of  the biologics license  application (BLA)  for  ocriplasmin intravitreal injection 2.5 mg/ml and granted it priority  review. The proposed  indication of ocriplasmin intravitreal injection is for the treatment of  symptomatic vitreomacular adhesion  (VMA) including macular hole.

The  FDA has scheduled an advisory  committee meeting on July 26  to discuss the ocriplasmin BLA and has assigned  the ocriplasmin BLA a prescription drug  user fee  act goal  date of Oct. 17.

Ocriplasmin has successfully completed two phase  III clinical trials for the pharmacologic treatment of symptomatic VMA,  including that associated with macular hole. The marketing authorization  application for ocriplasmin has been accepted for review in Europe.

ThromboGenics NV has announced that the FDA has accepted the filing of the biologics license application (BLA) for ocriplasmin intravitreal injection 2.5 mg/ml and granted it priority review. The proposed indication of ocriplasmin intravitreal injection is for the treatment of symptomatic vitreomacular adhesion (VMA) including macular hole.